The Study of ICP-248 in Patients with Mature B-cell Malignancies
- Conditions
- Hematological Malignancies
- Interventions
- Drug: ICP-248+Orelabrutinib
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 191
- Registration Number
- NCT05728658
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05719701
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: ICP-332 Placebo
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05702268
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
- Conditions
- Advanced Solid Tumors and Hematologic Malignancies
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT05690581
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus, SLE
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT05688696
- Locations
- 🇨🇳
Jilin Provincial People's Hospital, Changchun, Jilin, China
🇨🇳Daqing Oilfield General Hospital, Daqing, Heilongjiang, China
🇨🇳Yiyang Central Hospital, Yiyang, Hunan, China
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05684653
- Locations
- 🇨🇳
The First Affilitaed Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affilitaed Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Shulan (Hangzhou) hospital, Hangzhou, Zhejiang, China
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT05678270
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
- Conditions
- Healthy Subject
- Interventions
- Drug: Placebo (orelabrutinib tablet simulator)
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05660720
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, China
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05552937
- Locations
- 🇨🇳
The First Afflicated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 154
- Registration Number
- NCT05451199
- Locations
- 🇨🇳
Shiyan Renmin Hospital, Shiyan, Hubei, China
🇨🇳Yanbian University Hospital, Yanji, Jilin, China
🇨🇳Hangzhou First People's Hospital, Hangzhou, Zheajing, China